NCX 1022

Identification

Name
NCX 1022
Accession Number
DB05410
Type
Small Molecule
Groups
Investigational
Description

NCX is an NO-releasing derivative of hydrocortisone.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in atopic dermatitis.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

NCX 1022 is designed to have potent anti- inflammatory activity combined with a significantly improved safety and tolerability profile, in particular the absence of skin blanching after repeated use.It is better than hydrocortisone in terms of inhibiting benzalkonium chloride-induced leukocyte adhesion to the endothelium, without affecting the flux of rolling leukocytes or venule diameter.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with NCX 1022.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with NCX 1022.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with NCX 1022.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with NCX 1022.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with NCX 1022.Approved, Withdrawn
AldesleukinNCX 1022 may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of NCX 1022 can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of NCX 1022 can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of NCX 1022 can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with NCX 1022.Experimental
AloglutamolThe bioavailability of NCX 1022 can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with NCX 1022.Experimental
AluminiumThe bioavailability of NCX 1022 can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of NCX 1022 can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of NCX 1022 can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of NCX 1022 can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with NCX 1022.Approved
AmiodaroneThe serum concentration of NCX 1022 can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BNCX 1022 may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with NCX 1022.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with NCX 1022.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with NCX 1022.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with NCX 1022.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with NCX 1022.Approved, Investigational
AprepitantThe serum concentration of NCX 1022 can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of NCX 1022 can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of NCX 1022.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with NCX 1022.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with NCX 1022.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with NCX 1022.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with NCX 1022.Experimental
BendroflumethiazideNCX 1022 may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with NCX 1022.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with NCX 1022.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with NCX 1022.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with NCX 1022.Experimental
Bismuth SubcitrateThe bioavailability of NCX 1022 can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of NCX 1022 can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of NCX 1022 can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with NCX 1022.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with NCX 1022.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with NCX 1022.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with NCX 1022.Experimental
BumetanideNCX 1022 may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with NCX 1022.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of NCX 1022 can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of NCX 1022 can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideNCX 1022 may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of NCX 1022 can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with NCX 1022.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with NCX 1022.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with NCX 1022.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with NCX 1022.Approved, Investigational
CeritinibNCX 1022 may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with NCX 1022.Approved, Vet Approved
ChlorothiazideNCX 1022 may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of NCX 1022 can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneNCX 1022 may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of NCX 1022 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with NCX 1022.Approved
CinoxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of NCX 1022 can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with NCX 1022.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when NCX 1022 is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of NCX 1022 can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of NCX 1022 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of NCX 1022 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of NCX 1022 can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with NCX 1022.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when NCX 1022 is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with NCX 1022.Investigational
CyclopenthiazideNCX 1022 may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with NCX 1022.Investigational
DaidzeinThe serum concentration of NCX 1022 can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of NCX 1022 can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with NCX 1022.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with NCX 1022.Approved, Vet Approved
DienestrolThe serum concentration of NCX 1022 can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of NCX 1022 can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with NCX 1022.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with NCX 1022.Approved
DihydrotestosteroneNCX 1022 may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with NCX 1022.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with NCX 1022.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with NCX 1022.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of NCX 1022 can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of NCX 1022 can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with NCX 1022.Approved
EquolThe serum concentration of NCX 1022 can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of NCX 1022 can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of NCX 1022 can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of NCX 1022 can be increased when it is combined with Estrone.Approved
Etacrynic acidNCX 1022 may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with NCX 1022.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with NCX 1022.Experimental
Ethinyl EstradiolThe serum concentration of NCX 1022 can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with NCX 1022.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with NCX 1022.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with NCX 1022.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with NCX 1022.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with NCX 1022.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with NCX 1022.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with NCX 1022.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with NCX 1022.Approved
FenthionThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with NCX 1022.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with NCX 1022.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with NCX 1022.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with NCX 1022.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with NCX 1022.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with NCX 1022.Experimental
FluoxymesteroneNCX 1022 may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with NCX 1022.Approved, Investigational
FosaprepitantThe serum concentration of NCX 1022 can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of NCX 1022 can be decreased when it is combined with Fosphenytoin.Approved
FurosemideNCX 1022 may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when NCX 1022 is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of NCX 1022 can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when NCX 1022 is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492NCX 1022 may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with NCX 1022.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with NCX 1022.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with NCX 1022.Experimental
HexestrolThe serum concentration of NCX 1022 can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with NCX 1022.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with NCX 1022.Approved, Investigational
HydrochlorothiazideNCX 1022 may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideNCX 1022 may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of NCX 1022 can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with NCX 1022.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with NCX 1022.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with NCX 1022.Approved
IdelalisibThe serum concentration of NCX 1022 can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with NCX 1022.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of NCX 1022.Approved
IndapamideNCX 1022 may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of NCX 1022 can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with NCX 1022.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with NCX 1022.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with NCX 1022.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when NCX 1022 is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when NCX 1022 is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with NCX 1022.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with NCX 1022.Withdrawn
ItraconazoleThe serum concentration of NCX 1022 can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with NCX 1022.Experimental
KetoconazoleThe serum concentration of NCX 1022 can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with NCX 1022.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with NCX 1022.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with NCX 1022.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with NCX 1022.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with NCX 1022.Experimental
LopinavirThe serum concentration of NCX 1022 can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with NCX 1022.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with NCX 1022.Approved
LumacaftorThe serum concentration of NCX 1022 can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with NCX 1022.Approved, Investigational
MagaldrateThe bioavailability of NCX 1022 can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of NCX 1022 can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of NCX 1022 can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of NCX 1022 can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with NCX 1022.Approved
Magnesium silicateThe bioavailability of NCX 1022 can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of NCX 1022 can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with NCX 1022.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 1022.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with NCX 1022.Approved
MefloquineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with NCX 1022.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with NCX 1022.Approved
MesteroloneNCX 1022 may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of NCX 1022 can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with NCX 1022.Withdrawn
MethallenestrilThe serum concentration of NCX 1022 can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideNCX 1022 may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneNCX 1022 may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Metoclopramide.Approved, Investigational
MetolazoneNCX 1022 may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of NCX 1022 can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Minaprine.Approved
MitotaneThe serum concentration of NCX 1022 can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of NCX 1022.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with NCX 1022.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with NCX 1022.Experimental
MoxestrolThe serum concentration of NCX 1022 can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with NCX 1022.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with NCX 1022.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with NCX 1022.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with NCX 1022.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with NCX 1022.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Nalidixic Acid.Approved
NandroloneNCX 1022 may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with NCX 1022.Approved, Vet Approved
NefazodoneThe serum concentration of NCX 1022 can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of NCX 1022 can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with NCX 1022.Approved
NevirapineThe serum concentration of NCX 1022 can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with NCX 1022.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with NCX 1022.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with NCX 1022.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with NCX 1022.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with NCX 1022.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with NCX 1022.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with NCX 1022.Vet Approved
OxandroloneNCX 1022 may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with NCX 1022.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Oxolinic acid.Experimental
OxymetholoneNCX 1022 may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with NCX 1022.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with NCX 1022.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with NCX 1022.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of NCX 1022 can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of NCX 1022 can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with NCX 1022.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with NCX 1022.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with NCX 1022.Approved, Investigational
PhenytoinThe serum concentration of NCX 1022 can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with NCX 1022.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Pipemidic acid.Experimental
PiretanideNCX 1022 may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with NCX 1022.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with NCX 1022.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with NCX 1022.Experimental
Polyestradiol phosphateThe serum concentration of NCX 1022 can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideNCX 1022 may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of NCX 1022 can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with NCX 1022.Experimental
PrimidoneThe serum concentration of NCX 1022 can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with NCX 1022.Experimental
PromestrieneThe serum concentration of NCX 1022 can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with NCX 1022.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with NCX 1022.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with NCX 1022.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with NCX 1022.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of NCX 1022 can be increased when it is combined with Quinestrol.Approved
QuinethazoneNCX 1022 may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of NCX 1022.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 1022.Experimental, Investigational
RifabutinThe serum concentration of NCX 1022 can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of NCX 1022 can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of NCX 1022 can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of NCX 1022 can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with NCX 1022.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Rosoxacin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with NCX 1022.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with NCX 1022.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with NCX 1022.Approved
SaquinavirThe serum concentration of NCX 1022 can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of NCX 1022 can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with NCX 1022.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with NCX 1022.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with NCX 1022.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when NCX 1022 is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with NCX 1022.Investigational
St. John's WortThe serum concentration of NCX 1022 can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololNCX 1022 may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of NCX 1022 can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with NCX 1022.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with NCX 1022.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with NCX 1022.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with NCX 1022.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of NCX 1022 can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of NCX 1022 can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with NCX 1022.Investigational
TecemotideThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with NCX 1022.Withdrawn
TelithromycinThe serum concentration of NCX 1022 can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with NCX 1022.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with NCX 1022.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with NCX 1022.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with NCX 1022.Approved
TestosteroneNCX 1022 may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when NCX 1022 is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with NCX 1022.Approved
TiboloneThe serum concentration of NCX 1022 can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with NCX 1022.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with NCX 1022.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with NCX 1022.Approved
TorasemideNCX 1022 may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with NCX 1022.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with NCX 1022.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Trichlorfon.Vet Approved
TrichlormethiazideNCX 1022 may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with NCX 1022.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with NCX 1022.Investigational, Withdrawn
VoriconazoleThe serum concentration of NCX 1022 can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinNCX 1022 may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with NCX 1022.Approved
ZeranolThe serum concentration of NCX 1022 can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with NCX 1022.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with NCX 1022.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when NCX 1022 is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Hyun E, Bolla M, Steinhoff M, Wallace JL, Soldato PD, Vergnolle N: Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25. Epub 2004 Aug 16. [PubMed:15313880]
External Links
Not Available
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:24 / Updated on August 17, 2016 12:24